Fair-Value Report — Meilleure Health International (2327.HK)
Insider Signal
| Field | Detail |
|---|---|
| Filer | U-Home Group International Ltd |
| Relationship | Concert party of Executive Co-Chairman Zhou Xuzhou (周旭洲); group combined interest 63.32% |
| HKEX Reason Code | 1101 — On-exchange purchase (secondary market) |
| Event Date | 2026-07-16 |
| Trade Value | HKD 7,500,000 |
| Approx. Shares | ~30,000,000 at HKD 0.25 |
| Δ Holding | +0.97 percentage points |
| Post-Event Holding (U-Home Intl only) | 24.52% |
| Combined Group Holding | ~63.32% (Zhou Xuzhou and concert parties) |
Source: HKEX Disclosure of Interests (DI), lixinger.com shareholders data (2026-07-16). Purchase is genuine secondary-market acquisition; no concurrent placing or rights-issue announcement was identified around this date.
Verified Snapshot
| Balance Sheet Item | HKD M (FY2025) | Note |
|---|---|---|
| Total Assets | 1,815.6 | Primarily investment properties + financial assets at FV |
| Total Equity (attributable) | 1,248.2 | = Book NAV proxy |
| Total Liabilities | 567.4 | Implied (Assets minus Equity) |
| Est. Financial Debt | ~381 | D/E 30.52% × equity; includes Haitong facilities |
| Net Debt (est.) | n/a | Cash not separately confirmed; likely net debt given liabilities |
Sources: Investing.com / cn.investing.com financial summary (delayed data 2026-07-19); Sohu article (2026-03-27 results announcement); lixinger.com shareholders data. All figures in HKD unless noted.
Business Description
Meilleure Health International Industry Group Ltd (formerly U-Home Group Holdings Ltd — renamed to reflect a healthcare pivot) is a Bermuda-incorporated investment holding company listed on the HKEX Main Board since October 2003. The company operates through four reportable segments:
| Segment | Activities | FY2025 Trend |
|---|---|---|
| Healthcare-Related | Health management, aesthetic medicine, CBD/healthcare products | Sharply lower (building materials sales down) |
| Trading | Construction materials, renewable energy (photovoltaic) components | Sharply lower (international trade volumes reduced) |
| Property-Related | Rental income (including Jiangsu Yide, acquired Jan 2026); investment property FV | Growing (FV uplift + Jiangsu Yide) |
| Equity Investment | Direct equity holdings marked to FVTPL | Turned to loss (FV decline on portfolio) |
Key corporate actions (2025–2026)
- Jiangsu Yide acquisition (Jan 2026, connected transaction): Paid RMB 125M (~HKD 136M) to acquire 100% of Jiangsu Yide from related parties Yuye Group and Ms. Tan Wensheng. Jiangsu Yide holds 17 commercial + 3 residential properties + 34 parking spaces (~5,306 sqm) in Nanjing, generating ~RMB 7.8M/year rent (rental yield on cost: 5.97%). Stock fell >5% on announcement. Approved at SGM (April 2026). Governance concern: vendor relationship to management not fully transparent in public filings.
- 2026 Share Award Scheme (approved April 2026 SGM): Potential further dilution to minority shareholders; scale not yet known.
- Share buybacks & cancellation (June 2026): Cancelled 33.07M previously repurchased shares, modestly reducing total share count.
- Haitong pledge positions: HKEX DI records show Haitong UT Leasing HK Ltd (24.10%, dated 2022) and Haitong International Finance (13.31%, dated 2018) holding stakes — likely as secured creditors against loans from controlling-group entities. If still active, these pledged blocks represent forced-sale overhang risk if the share price declines.
Valuation — Method: Discount-to-Book NAV
Method rationale: Meilleure Health is an investment holding company whose balance sheet consists primarily of investment properties and equity financial assets, both already carried at fair value under HKFRS. There is no meaningful operating free cash flow on which to base a DCF. The standard approach is to assess the quality of reported NAV (book equity = HKD 1,248M = HKD 0.309/share) and apply a holding-company discount reflecting: (1) asset quality risk, (2) management track record, (3) governance concerns, and (4) free-float illiquidity.
Scenario table — NAV discount analysis
| Scenario | NAV Discount | FV/Share (HKD) | Key Assumptions |
|---|---|---|---|
| Bull | 15% | 0.263 | All assets at stated fair value; Nanjing property holds value; no hidden impairment; business stabilises |
| Base | 30% | 0.216 | Modest China property haircut; equity portfolio partially impaired; Jiangsu Yide acquisition at fair value; deteriorating operations continue |
| Bear | 50% | 0.155 | Significant China property impairment; connected-transaction assets overvalued; Haitong pledges become forced sales; further dilution from Share Award Scheme |
| Probability-weighted (25/50/25) | — | 0.212 | Default weighting applied |
Justified P/B fundamental check
Using Gordon Growth P/B: P/B = (ROE − g) / (CoE − g)
| Parameter | Value | Source / Notes |
|---|---|---|
| ROE (FY2025) | 3.1% | Net profit HKD 37.98M ÷ avg equity ~HKD 1,248M; almost entirely non-cash gains |
| Cost of Equity (CoE) | 12.0% | HK risk-free ~4.0% + ERP 8.0% (Damodaran; HK / China blend); micro-cap, China property, governance premia |
| Terminal growth (g) | 0% | Revenue in secular decline; no growth catalyst identified |
| Justified P/B | 0.258× | (3.1% − 0%) / (12.0% − 0%) = 0.258 |
| Implied FV/Share | HKD 0.080 | 0.258 × HKD 0.309; extreme lower bound if ROE remains at 3.1% |
Note: The justified P/B is an extreme bound, not a price target. For investment holding companies where assets are already at fair value, NAV-discount is the primary method; P/B from ROE is a cross-check that quantifies how far returns are below the cost of equity.
Reverse read
At HKD 0.25, the market prices 2327 at an 18.9% discount to book. For this to represent fair value, the company would need sustained ROE of approximately 9.7% (= CoE × P/B = 12% × 0.81). Current ROE of 3.1% is less than one-third of this implied level. Unless investment properties appreciate significantly beyond book or the operating business undergoes a genuine turnaround, the stock is trading above what fundamentals justify.
Peer context — HK small-cap diversified/investment holding companies
| Metric | 2327.HK | Sector typical range* | Notes |
|---|---|---|---|
| P/B | 0.81× | 0.30×–0.60× | 2327 trades at a PREMIUM to typical peers with comparable ROE |
| ROE | 3.1% | 2%–8% | Within range but at low end; profits non-cash |
| Revenue growth (1Y) | −28% | −5% to +5% | Severe underperformance |
| Net profit margin | 104% | 5%–30% | Anomalous — profit driven entirely by non-cash fair value changes |
| D/E ratio | 30.5% | 20%–80% | Moderate leverage; Haitong facilities add complexity |
| Dividend yield | 2.2% | 1%–4% | Reasonable but sustainability questionable (non-cash earnings) |
*Peer range is indicative for HK Main Board small-cap (<HKD 2B) diversified holding companies with declining revenues and non-cash earnings basis; based on sector norms. Specific peer tickers not listed due to data limitation. 2327 trades at a premium P/B relative to the peer group despite one of the worst revenue trajectories, suggesting overvaluation.
Conclusion
| Dimension | Assessment |
|---|---|
| Signal quality | LOW — controlling-party concert vehicle buying, not independent investor. Controlling group already at 63.32%; HKD 7.5M purchase is 0.74% of market cap. Motive could be control maintenance, signalling, or routine accumulation rather than deep value conviction. |
| Business quality | WEAK — revenue collapsed 96% since 2019; 42 employees; no meaningful operating FCF; profits are accounting line items (FV gains), not cash earnings. |
| Balance sheet | ADEQUATE but OPAQUE — HKD 1,248M book equity with large China property exposure; Jiangsu Yide acquisition (connected, RMB 125M) adds execution and governance risk; Haitong pledges add overhang uncertainty. |
| Valuation | FULL TO SLIGHTLY STRETCHED — at 0.81× P/B, the stock prices in near-zero quality haircut on NAV; justified P/B from ROE/CoE analysis is 0.26×; base-case NAV-discount FV is HKD 0.21 (−16% vs current price). |
| Catalysts | NONE IDENTIFIED — no privatisation bid filed; no transformative new business; 2026 Share Award Scheme adds dilution. |
Rating: HOLD
Fair value (base case): HKD 0.21 vs current price HKD 0.25 (as of 2026-07-16) — approximately 16% above base-case fair value. The insider signal is real but carries minimal information content (controlling party, incremental stake top-up). The operating business is in terminal revenue decline; reported profits are non-cash and do not support the dividend long-term. At 0.81× P/B for a company with 3.1% ROE, the stock appears modestly overvalued relative to peers and fundamental P/B benchmarks. A 30–40% discount to NAV (= HKD 0.185–0.216) is our anchor. Hold for existing shareholders; do not buy on this signal alone. Re-evaluate if: (a) a privatisation offer emerges (given 63% controlling stake, plausible long-term), (b) property asset values are independently verified at premium to book, or (c) operating revenues show sustained recovery.
Key Risks
- China property impairment: Investment properties in mainland China (including Nanjing/Jiangsu Yide assets) are subject to ongoing sector stress; fair-value marks may overstate recoverable values.
- Connected-transaction governance: Repeated related-party acquisitions (Jiangsu Yide from Yuye Group/Tan Wensheng) raise questions about whether asset prices favour the controlling group at minorities' expense.
- Haitong pledge overhang: If pledged shares (~37% of total shares at peak DI filings) remain active, forced sales by Haitong in a declining share price environment could trigger a liquidity spiral.
- Dilution from Share Award Scheme: 2026 scheme approved at SGM; quantum unknown; any material issuance further dilutes per-share NAV and earnings.
- Dividend sustainability: The 2.2% yield is paid from non-cash profits; if investment properties and equity portfolios reverse, the accounting profit disappears and dividends could be cut.
- Revenue collapse continuation: All four segments face structural headwinds; there is no evidence of a revenue stabilisation floor.
- Illiquid float: With ~63% controlled by the Zhou Xuzhou concert party and possible Haitong pledge blocks, the effective free float is very small, leading to high bid-ask spreads and exit risk.
Sources
- HKEX Disclosure of Interests — 2327.HK, filing 2026-07-16 (reason 1101 on-exchange purchase, filer: U-Home Group International Ltd)
- HKEX Announcements — connected transaction announcement (Jiangsu Yide), January 2026; SGM results, April 2026; share cancellation, June 2026
- lixinger.com — major shareholder table for 02327, dated 2026-07-16
- Investing.com / cn.investing.com — financial summary for 2327.HK (delayed, as of 2026-07-19): revenue, net income, total assets, total equity, P/B, ROE, DY, D/E
- Sohu.com — 2025 annual results summary (published 2026-03-27): revenue HKD 36.52M, profit HKD 37.98M, EPS 0.93 HK cents
- Futunn / news.futunn.com — Zhongjia U-Home Investment Ltd shareholding disclosures, January and July 2026
- Sina Finance — historical financial data FY2016–FY2019 (revenue, assets, equity, per-share metrics)
- Sina Finance news — Jiangsu Yide acquisition details, January 2026 (Sina doc-inhfzqaw0035034)
- Minichart.com.sg — SGM results April 2026 (equity interest transfer and 2026 Share Award Scheme)
- Eastmoney / caifuhao.eastmoney.com — share cancellation June 2026; director purchase September 2024
- Investing.com company profile — business description, leadership, market details
No redactions applied.
Published via wiis. Originals are encrypted at rest; this page reflects the redacted version. report abuse.
Discussion
No comments yet.